COVID-19 and metabolic disease: mechanisms and clinical management

Charlotte Steenblock; Peter E H Schwarz; Barbara Ludwig; Andreas Linkermann; Paul Zimmet; Konstantin Kulebyakin; Vsevolod A Tkachuk; Alexander G Markov; Hendrik Lehnert; Martin Hrabě De Angelis; Hannes Rietzsch; Roman N Rodionov; Kamlesh Khunti; David Hopkins; Andreas L Birkenfeld; Bernhard Boehm; Richard I G Holt; Jay S Skyler; J Hans Devries; Eric Renard; Robert H Eckel; K George M M Alberti; Bruno Geloneze; Juliana C Chan; Jean Claude Mbanya; Henry C Onyegbutulem; Ambady Ramachandran; Abdul Basit; Mohamed Hassanein; Gavin Bewick; Giatgen A Spinas; Felix Beuschlein; Rüdiger Landgraf; Francesco Rubino; Geltrude Mingrone; Stefan R Bornstein

doi:10.1016/S2213-8587(21)00244-8

COVID-19 and metabolic disease: mechanisms and clinical management

Charlotte Steenblock, Peter E H Schwarz, Barbara Ludwig, Andreas Linkermann, Paul Zimmet, Konstantin Kulebyakin, Vsevolod A Tkachuk, Alexander G Markov, Hendrik Lehnert, Martin Hrabě De Angelis, Hannes Rietzsch, Roman N Rodionov, Kamlesh Khunti, David Hopkins, Andreas L Birkenfeld, Bernhard Boehm, Richard I G Holt, Jay S Skyler, J Hans Devries, Eric RenardRobert H Eckel, K George M M Alberti, Bruno Geloneze, Juliana C Chan, Jean Claude Mbanya, Henry C Onyegbutulem, Ambady Ramachandran, Abdul Basit, Mohamed Hassanein, Gavin Bewick, Giatgen A Spinas, Felix Beuschlein, Rüdiger Landgraf, Francesco Rubino, Geltrude Mingrone, Stefan R Bornstein

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19 but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders. In this Review, we provide an update on the mechanisms of how metabolic and endocrine disorders might predispose patients to develop severe COVID-19. Additionally, we update the practical recommendations and management of patients with COVID-19 and post-pandemic. Furthermore, we summarise new treatment options for patients with both COVID-19 and diabetes, and highlight current challenges in clinical management.

Lingua originale	English
pagine (da-a)	786-798
Numero di pagine	13
Rivista	THE LANCET DIABETES & ENDOCRINOLOGY
Volume	9
DOI	https://doi.org/10.1016/S2213-8587(21)00244-8
Stato di pubblicazione	Pubblicato - 2021

Keywords

Angiotensin-Converting Enzyme 2
COVID-19
Diabetes Mellitus
Disease Management
Humans
Hypertension
Metabolic Diseases
Non-alcoholic Fatty Liver Disease
Obesity

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/S2213-8587(21)00244-8

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Steenblock, C., Schwarz, P. E. H., Ludwig, B., Linkermann, A., Zimmet, P., Kulebyakin, K., Tkachuk, V. A., Markov, A. G., Lehnert, H., De Angelis, M. H., Rietzsch, H., Rodionov, R. N., Khunti, K., Hopkins, D., Birkenfeld, A. L., Boehm, B., Holt, R. I. G., Skyler, J. S., Devries, J. H., ... Bornstein, S. R. (2021). COVID-19 and metabolic disease: mechanisms and clinical management. THE LANCET DIABETES & ENDOCRINOLOGY, 9, 786-798. https://doi.org/10.1016/S2213-8587(21)00244-8

@article{111a7c4403bd4a07895f9ef6cfc4e68e,

title = "COVID-19 and metabolic disease: mechanisms and clinical management",

abstract = "Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19 but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders. In this Review, we provide an update on the mechanisms of how metabolic and endocrine disorders might predispose patients to develop severe COVID-19. Additionally, we update the practical recommendations and management of patients with COVID-19 and post-pandemic. Furthermore, we summarise new treatment options for patients with both COVID-19 and diabetes, and highlight current challenges in clinical management.",

keywords = "Angiotensin-Converting Enzyme 2, COVID-19, Diabetes Mellitus, Disease Management, Humans, Hypertension, Metabolic Diseases, Non-alcoholic Fatty Liver Disease, Obesity, Angiotensin-Converting Enzyme 2, COVID-19, Diabetes Mellitus, Disease Management, Humans, Hypertension, Metabolic Diseases, Non-alcoholic Fatty Liver Disease, Obesity",

author = "Charlotte Steenblock and Schwarz, {Peter E H} and Barbara Ludwig and Andreas Linkermann and Paul Zimmet and Konstantin Kulebyakin and Tkachuk, {Vsevolod A} and Markov, {Alexander G} and Hendrik Lehnert and {De Angelis}, {Martin Hrab{\v e}} and Hannes Rietzsch and Rodionov, {Roman N} and Kamlesh Khunti and David Hopkins and Birkenfeld, {Andreas L} and Bernhard Boehm and Holt, {Richard I G} and Skyler, {Jay S} and Devries, {J Hans} and Eric Renard and Eckel, {Robert H} and Alberti, {K George M M} and Bruno Geloneze and Chan, {Juliana C} and Mbanya, {Jean Claude} and Onyegbutulem, {Henry C} and Ambady Ramachandran and Abdul Basit and Mohamed Hassanein and Gavin Bewick and Spinas, {Giatgen A} and Felix Beuschlein and R{\"u}diger Landgraf and Francesco Rubino and Geltrude Mingrone and Bornstein, {Stefan R}",

year = "2021",

doi = "10.1016/S2213-8587(21)00244-8",

language = "English",

volume = "9",

pages = "786--798",

journal = "THE LANCET DIABETES & ENDOCRINOLOGY",

issn = "2213-8587",

publisher = "Amsterdam : Elsevier",

}

Steenblock, C, Schwarz, PEH, Ludwig, B, Linkermann, A, Zimmet, P, Kulebyakin, K, Tkachuk, VA, Markov, AG, Lehnert, H, De Angelis, MH, Rietzsch, H, Rodionov, RN, Khunti, K, Hopkins, D, Birkenfeld, AL, Boehm, B, Holt, RIG, Skyler, JS, Devries, JH, Renard, E, Eckel, RH, Alberti, KGMM, Geloneze, B, Chan, JC, Mbanya, JC, Onyegbutulem, HC, Ramachandran, A, Basit, A, Hassanein, M, Bewick, G, Spinas, GA, Beuschlein, F, Landgraf, R, Rubino, F, Mingrone, G & Bornstein, SR 2021, 'COVID-19 and metabolic disease: mechanisms and clinical management', THE LANCET DIABETES & ENDOCRINOLOGY, vol. 9, pagg. 786-798. https://doi.org/10.1016/S2213-8587(21)00244-8

TY - JOUR

T1 - COVID-19 and metabolic disease: mechanisms and clinical management

AU - Steenblock, Charlotte

AU - Schwarz, Peter E H

AU - Ludwig, Barbara

AU - Linkermann, Andreas

AU - Zimmet, Paul

AU - Kulebyakin, Konstantin

AU - Tkachuk, Vsevolod A

AU - Markov, Alexander G

AU - Lehnert, Hendrik

AU - De Angelis, Martin Hrabě

AU - Rietzsch, Hannes

AU - Rodionov, Roman N

AU - Khunti, Kamlesh

AU - Hopkins, David

AU - Birkenfeld, Andreas L

AU - Boehm, Bernhard

AU - Holt, Richard I G

AU - Skyler, Jay S

AU - Devries, J Hans

AU - Renard, Eric

AU - Eckel, Robert H

AU - Alberti, K George M M

AU - Geloneze, Bruno

AU - Chan, Juliana C

AU - Mbanya, Jean Claude

AU - Onyegbutulem, Henry C

AU - Ramachandran, Ambady

AU - Basit, Abdul

AU - Hassanein, Mohamed

AU - Bewick, Gavin

AU - Spinas, Giatgen A

AU - Beuschlein, Felix

AU - Landgraf, Rüdiger

AU - Rubino, Francesco

AU - Mingrone, Geltrude

AU - Bornstein, Stefan R

PY - 2021

Y1 - 2021

N2 - Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19 but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders. In this Review, we provide an update on the mechanisms of how metabolic and endocrine disorders might predispose patients to develop severe COVID-19. Additionally, we update the practical recommendations and management of patients with COVID-19 and post-pandemic. Furthermore, we summarise new treatment options for patients with both COVID-19 and diabetes, and highlight current challenges in clinical management.

AB - Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19 but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders. In this Review, we provide an update on the mechanisms of how metabolic and endocrine disorders might predispose patients to develop severe COVID-19. Additionally, we update the practical recommendations and management of patients with COVID-19 and post-pandemic. Furthermore, we summarise new treatment options for patients with both COVID-19 and diabetes, and highlight current challenges in clinical management.

KW - Angiotensin-Converting Enzyme 2

KW - COVID-19

KW - Diabetes Mellitus

KW - Disease Management

KW - Humans

KW - Hypertension

KW - Metabolic Diseases

KW - Non-alcoholic Fatty Liver Disease

KW - Obesity

KW - Angiotensin-Converting Enzyme 2

KW - COVID-19

KW - Diabetes Mellitus

KW - Disease Management

KW - Humans

KW - Hypertension

KW - Metabolic Diseases

KW - Non-alcoholic Fatty Liver Disease

KW - Obesity

UR - http://hdl.handle.net/10807/200870

U2 - 10.1016/S2213-8587(21)00244-8

DO - 10.1016/S2213-8587(21)00244-8

M3 - Article

SN - 2213-8587

VL - 9

SP - 786

EP - 798

JO - THE LANCET DIABETES & ENDOCRINOLOGY

JF - THE LANCET DIABETES & ENDOCRINOLOGY

ER -

COVID-19 and metabolic disease: mechanisms and clinical management

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo